Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy
Jun Wei(Jilin Medical University), Hongbo Chi(St. Jude Children's Research Hospital), Lingyun Long(Lanzhou University), Anil KC(St. Jude Children's Research Hospital), John G. Doench(Broad Institute), Seon Ah Lim(Ewha Womans University), Cliff Guy(St. Jude Children's Research Hospital), Yogesh Dhungana(St. Jude Children's Research Hospital), Beisi Xu(St. Jude Children's Research Hospital), Chenxi Qian(Wuhan University of Technology), Hongling Huang(Xiamen University), Yong‐Dong Wang(St. Jude Children's Research Hospital), Jiyang Yu(Columbia University Irving Medical Center), Wenting Zheng(Fujian University of Technology), Jordy Saravia(St. Jude Children's Research Hospital), Yanyan Wang(Sichuan University), Terrence L. Geiger(St. Jude Children's Research Hospital)
Cited by 445
Related Papers
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
|Nature|2017|2k
HIF1α–dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells
|The Journal of Experimental Medicine|2011|1.8k
Regulation and function of mTOR signalling in T cell fate decisions
|Nature reviews. Immunology|2012|996
Discovering the anticancer potential of non-oncology drugs by systematic viability profiling
|Nature Cancer|2020|880